erlotinib has been researched along with Carcinoma, Hepatocellular in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El Hamid, MK; Abdelrahman, MH; Abou-Salim, MA; Elgazwi, SM; Elshaier, YAMM; Halaweish, F; Shaaban, MA | 1 |
1 other study(ies) available for erlotinib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Drug Design; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Models, Molecular; Nitric Oxide Donors; Pyrazoles; Pyrimidines | 2017 |